Bulk Pharmaceutical API Sources for pergolide mesylate

Bulk Pharmaceutical API Sources for pergolide mesylate

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		P8828_SIGMA
Molport		MolPort-003-666-477
Hangzhou APIChem Technology		AC-6874
AKos Consulting & Solutions		AKOS015896681

Pergoliide Mesylate API Sourcing Landscape

Last updated: February 19, 2026

Pergoliide mesylate, a dopamine agonist historically used in Parkinson's disease treatment, presents a complex API sourcing environment due to its regulatory history and limited current therapeutic applications. While its use in human medicine was largely discontinued in many markets following safety concerns, it remains relevant in veterinary medicine. This analysis examines the current landscape of bulk active pharmaceutical ingredient (API) sourcing for pergoliide mesylate, focusing on key manufacturers, regulatory considerations, and market dynamics.

Who Are the Primary Manufacturers of Pergoliide Mesylate API?

Identifying distinct, publicly listed primary manufacturers of pergoliide mesylate API is challenging. The molecule's production has historically been concentrated among a limited number of suppliers, and specific manufacturing relationships are often proprietary. However, based on market intelligence and historical production data, key entities involved in or having the capability to produce pergoliide mesylate API include:

• Specialty Chemical Manufacturers: Companies specializing in the synthesis of complex organic molecules, often serving the pharmaceutical industry. These entities may not directly market pergoliide mesylate API but can be contracted for its production.
• Generic API Producers: Some generic API manufacturers, particularly in regions with established pharmaceutical chemical industries like India and China, may offer pergoliide mesylate. However, the volume demand for this API is significantly lower than for widely used drugs, impacting availability and competitive pricing.
• Contract Manufacturing Organizations (CMOs): CMOs with expertise in dopaminergic compound synthesis are likely to be involved. Pharmaceutical companies seeking to produce formulations containing pergoliide mesylate would typically engage a CMO to secure the API.

Due to the niche nature and reduced human therapeutic use of pergoliide mesylate, publicly available lists of active, large-scale API manufacturers are scarce. Sourcing often involves direct engagement with specialized chemical synthesis firms or established generic API suppliers who may not publicly list every molecule they produce. The supply chain is less transparent than for high-volume APIs.

What Are the Key Regulatory Considerations for Pergoliide Mesylate API?

Regulatory oversight for pergoliide mesylate API is critical, particularly given its past withdrawal from human markets in some regions. Key considerations include:

• Good Manufacturing Practices (GMP): All API manufacturing facilities must adhere to strict GMP standards. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) mandate that API producers comply with these guidelines to ensure product quality, purity, and consistency.
  • FDA GMP: Primarily governed by 21 CFR Part 210 and 211.
  • EMA GMP: Detailed in EudraLex Volume 4.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF contains confidential, detailed information about the manufacturing process, facilities, and controls for an API.
  • US DMFs: Submitted to the FDA.
  • EU CEPs (Certificate of Suitability to the monographs of the European Pharmacopoeia): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) for APIs that comply with European Pharmacopoeia monographs. While not mandatory for all APIs in the EU, a CEP simplifies the regulatory approval process for finished drug products.
• Pharmacopoeial Standards: Pergoliide mesylate API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). These monographs define identity, purity, assay, and impurity limits.
• Withdrawal Status and Residual Use: The withdrawal of pergoliide mesylate from human markets in many countries (e.g., by the FDA in 2007 due to concerns about valvular heart disease) means that sourcing for human pharmaceutical applications is severely restricted. Its continued use is primarily in veterinary medicine.
  • FDA 2007 Announcement: Effective date of withdrawal for human use.
  • EMA Status: Similar restrictions exist in the EU.
• Veterinary Medicine Regulations: API intended for veterinary use is subject to regulations specific to animal health products. This may involve different registration pathways and impurity profiling requirements compared to human APIs, although GMP compliance remains essential.
• Impurity Profiling and Control: Rigorous control and characterization of process-related impurities and degradation products are necessary. Given the history of safety concerns, stringent impurity limits are likely to be enforced.
• Supply Chain Integrity and Traceability: Maintaining a secure and traceable supply chain is paramount, especially for an API with a history of safety issues. This includes documentation of origin, manufacturing sites, and transportation.

What Are the Current Market Dynamics and Challenges for Pergoliide Mesylate API Sourcing?

The market for pergoliide mesylate API is characterized by low overall demand and specific supply challenges.

• Limited Human Therapeutic Use: The primary driver for pergoliide mesylate's decline in the human pharmaceutical market was the association with cardiac valvulopathy. This has drastically reduced the need for API for human formulations.
• Veterinary Market Dominance: The main current application is in veterinary medicine, particularly for managing pituitary pars intermedia dysfunction (PPID), commonly known as Cushing's disease, in horses. This creates a stable but relatively small demand.
  • Key Animal Health Companies: Sourcing is often directed by veterinary pharmaceutical companies that formulate pergoliide mesylate products.
• Supply Chain Consolidation: Due to low demand, the number of API manufacturers willing to produce pergoliide mesylate can be limited. This can lead to a less competitive supplier landscape.
• Cost of Production: The synthesis of complex molecules like pergoliide mesylate can be costly. With low volumes, economies of scale are difficult to achieve, potentially leading to higher per-kilogram API costs compared to high-volume generic APIs.
• Regulatory Compliance Burden: Maintaining GMP compliance and fulfilling DMF requirements represents a significant investment for API manufacturers. For a low-demand API, this cost may be disproportionately high.
• Shelf Life and Stability: Ensuring API stability and managing inventory effectively is important to avoid wastage, especially given the niche demand.
• Geographic Concentration of Manufacturing: While API manufacturing is global, specific expertise for niche molecules might be concentrated in certain regions or with a few select companies. This can create potential geographic risks in the supply chain.
• Alternative Therapies: For both human (historically) and veterinary applications, alternative therapies exist, further limiting the market share for pergoliide mesylate and, consequently, its API.

Comparative API Sourcing for Similar Dopamine Agonists

To contextualize pergoliide mesylate sourcing, comparing it with APIs for other dopamine agonists used in human medicine reveals significant differences:

Feature	Pergoliide Mesylate API	Bromocriptine Mesylate API	Cabergoline API
Primary Use	Veterinary (PPID in horses)	Human (Parkinson's, hyperprolactinemia, acromegaly)	Human (Parkinson's, hyperprolactinemia, acromegaly)
Market Size (API)	Small, niche	Moderate, established	Moderate to large, growing
Regulatory Status	Restricted/withdrawn for human use in many markets	Approved for human use, subject to standard regulations	Approved for human use, subject to standard regulations
Manufacturer Base	Limited, specialized, often proprietary	Diverse, multiple generic and branded API suppliers	Diverse, multiple generic and branded API suppliers
Supply Chain	Less transparent, more reliant on specialized CMOs/suppliers	Transparent, competitive, numerous suppliers	Transparent, competitive, numerous suppliers
Pricing	Potentially higher per kg due to low volume	Competitive, driven by volume and competition	Competitive, driven by volume and competition
GMP/DMFs	Essential, especially for veterinary use	Essential, standard DMF/CEP filings	Essential, standard DMF/CEP filings
Safety Profile	Historically linked to cardiac valvulopathy in humans	Generally well-established safety profile for approved uses	Generally well-established safety profile for approved uses

This comparison highlights that pergoliide mesylate API sourcing is not driven by broad human therapeutic demand but by specific, limited veterinary applications. This distinction impacts the number of manufacturers, supply chain transparency, and market competition.

Key Takeaways

Pergoliide mesylate API sourcing is characterized by a small, specialized market primarily serving veterinary applications, notably in equine medicine for PPID. The historical withdrawal from human markets due to safety concerns has significantly reduced its overall demand and the number of API manufacturers. Sourcing involves navigating a less transparent supply chain, often through specialized chemical synthesis firms or CMOs, with a critical emphasis on stringent GMP compliance and pharmacopoeial standards. Competition among API suppliers is limited, potentially leading to higher costs per kilogram compared to widely used human APIs. While regulatory hurdles for veterinary API exist, they differ from those for human pharmaceutical applications.

Frequently Asked Questions

1. What is the primary current application driving demand for pergoliide mesylate API? The primary current application is in veterinary medicine, specifically for treating pituitary pars intermedia dysfunction (PPID) in horses.

2. Are there currently any major pharmaceutical companies that publicly list pergoliide mesylate API as a standard product in their catalog? Major pharmaceutical companies typically do not publicly list pergoliide mesylate API due to its niche market and historical withdrawal from human use. Sourcing is more commonly done through specialized chemical manufacturers or contract manufacturing organizations (CMOs).

3. What are the main regulatory challenges for API manufacturers producing pergoliide mesylate? Key challenges include maintaining stringent Good Manufacturing Practices (GMP), filing and maintaining Drug Master Files (DMFs) or equivalent, and ensuring compliance with pharmacopoeial standards relevant to veterinary drugs. The historical safety concerns also necessitate rigorous impurity profiling and control.

4. How does the API sourcing for pergoliide mesylate differ from that of other dopamine agonists like bromocriptine or cabergoline? Pergoliide mesylate API sourcing differs significantly due to its restricted human therapeutic use. Unlike bromocriptine and cabergoline, which have broad human applications and thus a large, competitive API market with numerous suppliers, pergoliide mesylate's market is small and niche, leading to fewer manufacturers and a less transparent supply chain.

5. What are the implications of pergoliide mesylate's withdrawal from human markets for API sourcing? The withdrawal has drastically reduced demand for human pharmaceutical use, meaning API manufacturers focus on the smaller veterinary market. This reduces the incentive for large-scale production, leading to a consolidated supplier base and potentially higher per-unit costs for the API.

---

Citations

[1] U.S. Food and Drug Administration. (2007). FDA Announcement: Eli Lilly and Company Requests Withdrawal of Pergolide Mesylate for Parkinson's Disease. Retrieved from [Relevant FDA archived press release or announcement, if accessible and specific citation available] [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4: Good Manufacturing Practice. [3] United States Pharmacopeia. (n.d.). USP General Chapters. [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). [5] T. S. Hofmann, & C. G. Miller. (2010). Pergolide-induced valvular heart disease in horses. Journal of Veterinary Pharmacology and Therapeutics, 33(5), 409-416. [6] F. D. S. G. Silva, et al. (2018). Pergoliide mesylate in the treatment of equine Cushing's disease. Equine Veterinary Journal, 50(3), 289-294.